Nexalin Technology Inc Asset Turnover Ratio (NXL), as of second quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Nexalin Technology Inc   (NASDAQ: NXL)
 

Nexalin Technology Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Nexalin Technology Inc 's asset turnover ratio, the ratio that measures the ability of Nexalin Technology Inc 's assets to generate revenue, sequentially decreased to 0.05 in the second quarter (Jun 30 2026), which does not come as a surprise, as the Nexalin Technology Inc continue to experience difficult business climate.

Within sector 170 more businesses have achieved higher asset turnover ratio. While Asset turnover ratio total ranking has improved so far during the II Quarter 2026, to 3378, from total ranking in the first quarter 2026 at 4073.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NXL Asset Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Asset Change -54.23 % 27.39 % 9.75 % -4.33 % 294.55 %
Y / Y Revenue Change -82.77 % -63.55 % 532.46 % -49.63 % 163 %
Asset Turnover Ratio (TTM) 0.05 0.06 0.06 0.03 0.04
NXL's Total Ranking # 3378 # 4073 # 3764 # 3733 # 3755
Seq. Asset Change -18.69 % -20.29 % -9.57 % -21.91 % 126.34 %
Seq. Revenue Change -18.66 % -91.3 % 847.13 % -74.29 % 72.1 %



Asset Turnover Ratio Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 171
Healthcare Sector # 506
Overall Market # 3378

Asset Turnover Ratio Statistics
High Average Low
0.18 0.06 0.02
(Mar 31 2023)   (Sep 30 2023)




NXL Company Profile • Back to NXL Efficiency Comparisons • Compare NXL Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Assets at quarter ending Jun 30 2026
Dariohealth Corp   0.20 $ 21.196  Millions$ 106.918  Millions
Safe Pro Group Inc   0.20 $ 2.881  Millions$ 14.769  Millions
60 Degrees Pharmaceuticals Inc   0.19 $ 1.111  Millions$ 5.775  Millions
Moderna Inc   0.19 $ 2,228.000  Millions$ 11,730.500  Millions
4d Molecular Therapeutics Inc   0.18 $ 92.008  Millions$ 499.053  Millions
Nrx Pharmaceuticals Inc   0.18 $ 3.394  Millions$ 18.504  Millions
Lexicon Pharmaceuticals Inc   0.18 $ 41.469  Millions$ 227.448  Millions
Bioadaptives Inc   0.18 $ 0.026  Millions$ 0.141  Millions
Foghorn Therapeutics Inc   0.18 $ 36.739  Millions$ 207.156  Millions
Renovorx Inc   0.18 $ 1.976  Millions$ 11.184  Millions
Coya Therapeutics Inc   0.18 $ 8.019  Millions$ 45.643  Millions
Ligand Pharmaceuticals Incorporated  0.17 $ 290.542  Millions$ 1,688.847  Millions
Septerna Inc   0.17 $ 98.882  Millions$ 584.816  Millions
Inspiremd Inc   0.17 $ 10.502  Millions$ 62.247  Millions
Prelude Therapeutics Inc  0.16 $ 22.424  Millions$ 136.269  Millions
Prothena Corporation Public Limited Company  0.16 $ 54.530  Millions$ 332.976  Millions
Opus Genetics Inc   0.16 $ 9.856  Millions$ 61.530  Millions
Skinvisible Inc   0.16 $ 0.020  Millions$ 0.126  Millions
Maxcyte inc   0.16 $ 31.051  Millions$ 198.782  Millions
Abeona Therapeutics Inc   0.15 $ 30.093  Millions$ 207.166  Millions
Voyager Therapeutics Inc   0.14 $ 34.459  Millions$ 239.417  Millions
Standard Biotools Inc   0.14 $ 83.691  Millions$ 593.430  Millions
Femasys Inc   0.14 $ 2.299  Millions$ 16.450  Millions
Seastar Medical Holding Corp  0.14 $ 1.713  Millions$ 12.400  Millions
Sintx Technologies Inc   0.14 $ 1.330  Millions$ 9.778  Millions
Xencor Inc  0.13 $ 104.973  Millions$ 801.528  Millions
Lucid Diagnostics Inc   0.13 $ 5.445  Millions$ 41.667  Millions
Royalty Pharma Plc  0.13 $ 2,535.998  Millions$ 19,650.812  Millions
Omniab Inc   0.13 $ 38.457  Millions$ 298.628  Millions
Lineage Cell Therapeutics Inc   0.13 $ 13.083  Millions$ 104.494  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.